Postoperative complications after radical treatment of cervical cancer: common pathogenetic mechanisms and modern possibilities for their prevention

Sumtsov D.G.

Main
Publications
Postoperative complications after radical treatment of cervical cancer: common pathogenetic mechanisms and modern possibilities for their prevention

August 25, 2026

Obstetrics and Gynecology

Oncology, Hematology

Sumtsov D.G.

УДК: 618.146-006.6-089.87

DOI: 10.32471/umj.1680-3051.280033

Keywords :

cervical cancer,

lymphedema,

pathogenetic therapy,

postoperative complications,

streptodornase,

streptokinase

Specialities :

Obstetrics and Gynecology

Oncology, Hematology

Resume

Radical treatment of cervical cancer is associated with the development of a wide range of postoperative complications, which can significantly affect the results of treatment and the quality of life of patients. The article reviews modern international approaches to their prevention and shows that, despite the diversity of clinical manifestations, most complications are formed according to a common pathogenetic scenario associated with the accumulation of excess fibrin, cellular detritus, extracellular DNA, Neutrophil Extracellular Traps (NETs) and thick exudate. Based on modern data, the pathogenetic justification for the use of a combination of streptokinase and streptodornase as a means of complex influence on the key mechanisms of postoperative inflammation is analyzed. The results of a domestic clinical study and clinical cases are presented, illustrating the practical importance of early pathogenetically oriented prevention of postoperative complications in patients after radical treatment of cervical cancer.

References

1. Cibula D., Planchamp F., Fischerova D. et al. (2023) ESGO/ESTRO/ESP Guidelines for the Management of Patients with Cervical Cancer — Update 2023. Int. J. Gynecol. Cancer, 33(5): 649–666. doi.org/10.1136/ijgc-2023-004429.
2. Berríos-Torres S.I., Umscheid C.A., Bratzler D.W. et al. (2017) Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg., 152(8): 784–791. doi.org/10.1001/jamasurg.2017.0904.
3. Allegranzi B., Bischoff P., de Jonge S. et al. (2016) New WHO Recommendations on Preoperative Measures for Surgical Site Infection Prevention: An Evidence-Based Global Perspective. Lancet Infect. Dis., 16(12). doi.org/10.1016/S1473-3099(16)30398-X.
4. ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. (2018) Obstet Gynecol., 131(6). doi.org/10.1097/AOG.0000000000002670.
5. Nelson G., Bakkum-Gamez J.N., Kalogera E. et al. (2023) Guidelines for Perioperative Care in Gynecologic Oncology: Enhanced Recovery After Surgery (ERAS®) Society Recommendations. World J. Surg.
6. Key N.S., Khorana A.A., Kuderer N.M. et al. (2023) Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J. Clin. Oncol., 41(16): 3063–3071. doi.org/10.1200/JCO.23.00294.
7. Falanga A., Ay C., Di Nisio M. et al. (2023) Venous Thromboembolism in Cancer Patients: ESMO Clinical Practice Guideline. Ann. Oncol., 34(5): 452–467. doi.org/10.1016/j.annonc.2022.12.014.
8. Gressel G.M., Marcus J.Z., Mullen M.M. et al. (2021) Direct Oral Anticoagulant Use in Gynecologic Oncology: A Society of Gynecologic Oncology Clinical Practice Statement. Gynecol. Oncol., 160(1): 312–321. doi.org/10.1016/j.ygyno.2020.11.020.
9. Executive Committee of the International Society of Lymphology (2023) The Diagnosis and Treatment of Peripheral Lymphedema: 2023 Consensus Document of the International Society of Lymphology. Lymphology, 56(4): 133–151.
10. Ferrari F.A., Giannini A., Pecorino B. et al. (2024) Minimally Invasive vs. Open Surgery: Comparison of Surgical Complications in Radical Hysterectomy for Cervical Cancer. Mini-invasive Surg., 8: 37. doi.org/10.20517/2574-1225.2024.50.
11. Saemathong T., Chaowawanit W. (2024) A Retrospective Study of Complications Following Pelvic and Para-Aortic Lymphadenectomy in Gynecologic Oncology. World J. Oncol., 15(3): 423–431. doi.org/10.14740/wjon1824.
12. Mercadel A.J., Lea J.S., Erickson B.K. et al. (2023) Risk Factors for Catheter-Associated Urinary Tract Infections After Radical Hysterectomy for Cervical Cancer. Int. Urogynecol. J., 34: 1709–1716. doi.org/10.1007/s00192-023-05507-5.
13. National Cancer Institute (2024) Lymphedema (PDQ®): Health Professional Version. http://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-hp-pdq.
14. Ostenfeld E.B., Schnack T.H., Jochumsen K.M. et al. (2025) Long-Term Lymphedema and Quality of Life Following Lymph Node Staging in Early Cervical Cancer: 3 Years Follow-Up in the Prospective Multicenter SENTIREC CERVIX Study. Am. J. Obstet. Gynecol. doi.org/10.1016/j.ajog.2025.09.020.
15. Bona A.F., de Oliveira M.A.P., Franco M.M. et al. (2020) Incidence, Prevalence, and Factors Associated With Lymphedema After Treatment for Cervical Cancer: A Systematic Review. Int. J. Gynecol. Cancer, 30(7): 1101–1110. doi.org/10.1136/ijgc-2020-001351.
16. Decorte T., Vermeiren K., Vergote I. et al. (2025) Risk Factors for Lower Limb Lymphedema After Gynecological Cancer Treatment: A Systematic Review. Front. Oncol., 15: 1561836. doi.org/10.3389/fonc.2025.1561836.
17. Chino J., Annunziata C.M., Beriwal S. et al. (2020) Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract. Radiat. Oncol., 10(4): 220–234. doi.org/10.1016/j.prro.2020.04.002.
18. Schmitt L.G., Small W. Jr., Klopp A.H. et al. (2023) Late Effects of Pelvic Radiation Therapy in the Female Patient: A Comprehensive Review. Appl. Radiat. Oncol., doi.org/10.37549/ARO-D-23-00016.
19. Risman R.A., Kirby N.C., Bannish B.E. et al. (2023) Fibrinolysis: An Illustrated Review. Res Pract. Thromb. Haemost., 7(2): 100081. doi.org/10.1016/j.rpth.2023.100081.
20. Huish S., Thelwell C., Longstaff C. (2017) Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus pyogenes. PLoS One, 12(1). doi.org/10.1371/journal.pone.0170936.
21. Miles L.A., Ny L., Wilczyńska M. et al. (2021) Plasminogen Receptors and Fibrinolysis. Int. J. Mol. Sci., 22(4): 1712. doi.org/10.3390/ijms22041712.
22. Arung W., Meurisse M., Detry O. (2011) Pathophysiology and Prevention of Postoperative Peritoneal Adhesions. World J. Gastroenterol., 17(41): 4545–4553. doi.org/10.3748/wjg.v17.i41.4545.
23. Hosseini A., Akhavan S., Menshaei M. et al. (2018) Effects of Streptokinase and Normal Saline on the Incidence of Intra-Abdominal Adhesion 1 Week and 1 Month After Laparotomy in Rats. Adv. Biomed. Res., 7: 16. doi.org/10.4103/abr.abr_225_16.
24. Cheung J.P., Tsang H.H., Cheung J.J. et al. (2009) Adjuvant Therapy for the Reduction of Postoperative Intra-Abdominal Adhesion Formation. Asian J. Surg., 32(3): 180–186. doi.org/10.1016/S1015-9584(09)60392-4.
25. Simpson G., Roomes D., Reeves B. (2000) Effects of Streptokinase and Deoxyribonuclease on Viscosity of Human Surgical and Empyema Pus. Chest, 117(6): 1728–1735. doi.org/10.1378/chest.117.6.1728.
26. Hellebrekers B.W., Trimbos-Kemper T.C., Trimbos J.B. et al. (2000) Use of Fibrinolytic Agents in the Prevention of Postoperative Adhesion Formation. Fertility and Sterility, 74(2): 203–212. doi.org/10.1016/S0015-0282(00)00656-7.
27. Flemming H.C., Wingender J. (2010) The Biofilm Matrix. Nat. Rev. Microbiol., 8(9): 623–633. doi.org/10.1038/nrmicro2415.
28. Papayannopoulos V. (2018) Neutrophil Extracellular Traps in Immunity and Disease. Nat. Rev. Immunol., 18(2): 134–147. doi.org/10.1038/nri.2017.105.
29. Tetz G.V., Artemenko N.K., Tetz V.V. (2009) Effect of DNase and Antibiotics on Biofilm Characteristics. Antimicrob Agents Chemother., 53(3): 1204–1209. doi.org/10.1128/AAC.00471-08.
30. Sturm M.C.K., Abazid A., Stope M.B. (2025) Tissue Adhesion After Surgical Interventions. Experimental and Therapeutic Medicine, 29(5): 97. doi.org/10.3892/etm.2025.12847.
31. Nemoto K., Hirota K., Murakami K. et al. (2003) Effect of Varidase (Streptodornase) on Biofilm Formed by Pseudomonas aeruginosa. Chemotherapy, 49(3): 121–125. doi.org/10.1159/000070617.
32. Інструкція для медичного застосування препарату Дістрептаза Дістрепт. http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlz1?opendocument&stype=951613D31606B0B4C2258DAB003CBFA0.
33. Пащенко С.М., Резніченко Г.І., Самсонова В.В. та ін. (2010) Ефективність застосування препарату Дістрептаза для профілактики післяопераційних гнійно-септичних ускладнень у хворих на рак товстого кишечнику. Сучасні медичні технології, 4: 19–22.